---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-009015"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T07:30:59.115763+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Windtree reports FY2022 net loss $39.2M; cash runway into Q2 2023 only

## Summary
- Q4 2022 net loss $9.7M ($13.01/share); FY2022 net loss $39.2M ($62.23/share).
- Operating loss Q4 $10.8M includes $6.8M rostafuroxin impairment; FY operating loss $41.3M includes $12.6M goodwill impairment.
- Cash and equivalents $6.2M at Dec 31, 2022; expects to fund operations into Q2 2023 only.
- Raised $1.0M from warrant exercises; R&D expense fell to $1.2M in Q4 from $4.5M YoY.
- Istaroxime SEISMiC study met primary endpoint (p=0.017) in early cardiogenic shock; new patent for longer infusion.

## SEC filing metadata
- accession: 0001437749-23-009015
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774923009015/0001437749-23-009015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774923009015/wint20221118b_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-009015
- JSON: https://secwatch.observer/filing/0001437749-23-009015.json
- Plain text: https://secwatch.observer/filing/0001437749-23-009015.txt

## Key facts
- Earnings Releases
  WINDTREE THERAPEUTICS INC /DE/ reported financial results for the fourth quarter and fiscal year ended December 31, 2022.
  - Period: the fourth quarter and fiscal year ended December 31, 2022
  - Result: reported results
  source text: On April 3, 2023, Windtree Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/946486/000143774923009015/0001437749-23-009015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.